BMS/Ambrx Deal Highlights Big Pharma’s Growing Interest in Protein Drug Engineering
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 10 (Table of Contents)
Published: 10 Oct-2011
DOI: 10.3833/pdr.v2011.i10.1571 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Bristol-Myers Squibb has partnered with Ambrx for the development and commercialisation of derivatives of fibroblast growth factor 21 (FGF-21) for the potential treatment of type 2 diabetes and derivatives of the hormone relaxin for the potential treatment of heart failure...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS